دورية أكاديمية
Preliminary Study on the Efficacy of a Recombinant, Subunit SARS-CoV-2 Animal Vaccine against Virulent SARS-CoV-2 Challenge in Cats
| العنوان: | Preliminary Study on the Efficacy of a Recombinant, Subunit SARS-CoV-2 Animal Vaccine against Virulent SARS-CoV-2 Challenge in Cats |
|---|---|
| المؤلفون: | Igor Morozov, Natasha N. Gaudreault, Jessie D. Trujillo, Sabarish V. Indran, Konner Cool, Taeyong Kwon, David A. Meekins, Velmurugan Balaraman, Bianca Libanori Artiaga, Daniel W. Madden, Chester McDowell, Bradley Njaa, Jamie Retallick, Nicole Hainer, Jason Millership, William C. Wilson, George Tkalcevic, Hanne Vander Horst, Yulia Burakova, Vickie King, Kendra Hutchinson, John M. Hardham, Denise J. Schwahn, Mahesh Kumar, Juergen A. Richt |
| المصدر: | Vaccines, Vol 11, Iss 12, p 1831 (2023) |
| بيانات النشر: | MDPI AG, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | SARS-CoV-2, cats, feline, recombinant vaccine, virus-neutralizing antibodies, immune response, Medicine |
| الوصف: | The objective of this work was to evaluate the safety and efficacy of a recombinant, subunit SARS-CoV-2 animal vaccine in cats against virulent SARS-CoV-2 challenge. Two groups of cats were immunized with two doses of either a recombinant SARS-CoV-2 spike protein vaccine or a placebo, administered three weeks apart. Seven weeks after the second vaccination, both groups of cats were challenged with SARS-CoV-2 via the intranasal and oral routes simultaneously. Animals were monitored for 14 days post-infection for clinical signs and viral shedding before being humanely euthanized and evaluated for macroscopic and microscopic lesions. The recombinant SARS-CoV-2 spike protein subunit vaccine induced strong serologic responses post-vaccination and significantly increased neutralizing antibody responses post-challenge. A significant difference in nasal and oral viral shedding, with significantly reduced virus load (detected using RT-qPCR) was observed in vaccinates compared to mock-vaccinated controls. Duration of nasal, oral, and rectal viral shedding was also significantly reduced in vaccinates compared to controls. No differences in histopathological lesion scores were noted between the two groups. Our findings support the safety and efficacy of the recombinant spike protein-based SARS-CoV-2 vaccine which induced high levels of neutralizing antibodies and reduced nasal, oral, and rectal viral shedding, indicating that this vaccine will be efficacious as a COVID-19 vaccine for domestic cats. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 11121831 2076-393X |
| Relation: | https://www.mdpi.com/2076-393X/11/12/1831; https://doaj.org/toc/2076-393X |
| DOI: | 10.3390/vaccines11121831 |
| URL الوصول: | https://doaj.org/article/314f5e2000de4c84b8e72ad714604fa4 |
| رقم الأكسشن: | edsdoj.314f5e2000de4c84b8e72ad714604fa4 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 11121831 2076393X |
|---|---|
| DOI: | 10.3390/vaccines11121831 |